1. Home
  2. DUO vs NVNO Comparison

DUO vs NVNO Comparison

Compare DUO & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.59

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

HOLD

Current Price

$0.34

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
NVNO
Founded
2011
1987
Country
China
United States
Employees
N/A
N/A
Industry
Real Estate
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
DUO
NVNO
Price
$1.59
$0.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
66.1K
539.5K
Earning Date
03-13-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$56,189,313.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.30
N/A
52 Week Low
$1.24
$0.30
52 Week High
$11.46
$5.62

Technical Indicators

Market Signals
Indicator
DUO
NVNO
Relative Strength Index (RSI) 44.25 47.06
Support Level $1.54 $0.33
Resistance Level $1.68 $0.38
Average True Range (ATR) 0.09 0.04
MACD 0.01 0.01
Stochastic Oscillator 40.00 47.92

Price Performance

Historical Comparison
DUO
NVNO

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: